Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1135-1140

  Jeong, J ^a   Jeung, H C ^a,b   Rha, S Y ^a,b   Im, C K ^a,b   Shin, S J ^a,b   Ahn, J B ^a,b   Noh, S H ^a   Roh, J K ^a,b   Chung, H C ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Advanced gastric cancer; Leucovorin; Oxaliplatin; Salvage chemotherapy

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TRANSFUSION; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; STOMACH NEOPLASMS;

EID: 44849088035     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn013     Document Type: Article

References (25)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.
2. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Onool 2005; 17: 81-90.
3. Lacave AJ, Izarzugaza I, Anton Aparicio LM et al. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 1983; 6: 35-38.
4. Lacave AJ, Wils J, Diaz-Rubio E et al. cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 1985; 21: 1321-1324.
5. Ohtsu A, Yoshida S, Saito D et al. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991; 21: 120-124.
6. Cascinu S, Graziano F, Cardarelli N et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998; 9: 307-310.
7. Stathopoulos GP, Rigatos SK, Fountzilas G et al. Paclitaxel and carboplatin in pretreated advanced gastric cancer: A phase II study. Oncol Rep 2002; 9: 89-92.
8. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323.
9. Shimada S, Yagi Y, Kuramoto M et al. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-flouracil. Oncol Rep 2003; 10: 687-691.
10. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexan eplatinum(II) complexes. Chem Biol Interact 1989; 70: 39-49.
11. Dunn TA, Schmoll HJ, Grünwald V et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997; 15: 109-114.
12. Fukuda M, Ohe Y, Kanzawa F et al. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995; 15: 393-398.
13. De Vita F, Orditura M, Matano E et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOI FOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92: 1644-1649.
14. Lordick F, Lorenzen S, Stollfuss J et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005; 93: 190-194.
15. Louvet C, Andr T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patents. J Clin Oncol 2002; 20: 4543-4548.
16. de Gramont A, Tournigand C, Louvet C et al. (Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]. Rev Med Interne 1997; 18: 769-775.
17. Qin B, Tanaka R, Shibata Y et al. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. Anticancer Drugs 2006; 17: 445-453.
18. Yoshida S, Miyata Y, Ohtsu A et al. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 2000; 3: 128-133.
19. Yoo CH, Noh SH, Shin DW et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242.
20. Graziano F, Catalano V, Baldelli AM et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263-1266.
21. Hartmann JT, Quietzsch D, Daikeler T et al. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs 1999; 10: 729-733.
22. Schmid KE, Kornek GV, Schüll B et al. Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie 2003; 26: 255-258.
23. Vanhoofer U, Wilke H, Web HJ et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994; 5: 850-851.
24. Kim DY, Kim JH, Lee SH et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-beated patients with advanced gastric cancer. Ann Onool 2003; 14: 383-387.
25. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25: 13-22.